Humacyte (NASDAQ:HUMA) Downgraded by Wall Street Zen to Strong Sell

Wall Street Zen downgraded shares of Humacyte (NASDAQ:HUMA) from a sell rating to a strong sell rating in a report published on Saturday.

A number of other research analysts have also recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a research note on Wednesday, July 8th. Benchmark cut their target price on Humacyte from $2.00 to $1.00 and set a “speculative buy” rating for the company in a research note on Thursday. BTIG Research reaffirmed a “buy” rating and issued a $2.00 target price on shares of Humacyte in a report on Wednesday. D. Boral Capital reissued a “buy” rating and set a $25.00 price target on shares of Humacyte in a report on Tuesday, April 28th. Finally, TD Cowen lowered their price target on Humacyte from $1.50 to $1.25 and set a “buy” rating for the company in a report on Wednesday, June 17th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $6.11.

Humacyte Trading Up 10.0%

HUMA opened at $0.60 on Friday. Humacyte has a twelve month low of $0.53 and a twelve month high of $2.55. The company has a 50-day simple moving average of $0.78 and a 200 day simple moving average of $0.90. The company has a quick ratio of 3.32, a current ratio of 6.21 and a debt-to-equity ratio of 2.07. The stock has a market capitalization of $163.08 million, a price-to-earnings ratio of -1.23 and a beta of 2.53.

Humacyte (NASDAQ:HUMA) last released its earnings results on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.05). The firm had revenue of $0.41 million during the quarter, compared to the consensus estimate of $1.04 million. Humacyte had a negative net margin of 4,556.29% and a negative return on equity of 983.32%. Analysts predict that Humacyte will post -0.38 EPS for the current fiscal year.

Insider Buying and Selling at Humacyte

In other news, insider Shamik J. Parikh sold 45,887 shares of Humacyte stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $0.90, for a total transaction of $41,298.30. Following the sale, the insider directly owned 272,713 shares of the company’s stock, valued at approximately $245,441.70. This trade represents a 14.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kathleen Sebelius purchased 56,818 shares of Humacyte stock in a transaction dated Tuesday, May 19th. The shares were purchased at an average price of $0.88 per share, for a total transaction of $49,999.84. Following the completion of the acquisition, the director owned 148,025 shares of the company’s stock, valued at approximately $130,262. The trade was a 62.30% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Humacyte

A number of institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its stake in shares of Humacyte by 33.4% during the second quarter. Geode Capital Management LLC now owns 2,948,508 shares of the company’s stock valued at $6,163,000 after acquiring an additional 738,142 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Humacyte by 31.3% in the second quarter. JPMorgan Chase & Co. now owns 70,067 shares of the company’s stock valued at $146,000 after purchasing an additional 16,702 shares during the period. Rhumbline Advisers increased its holdings in Humacyte by 51.1% in the second quarter. Rhumbline Advisers now owns 177,623 shares of the company’s stock valued at $371,000 after purchasing an additional 60,059 shares during the period. Prudential Financial Inc. bought a new position in Humacyte during the 2nd quarter worth $28,000. Finally, Marshall Wace LLP lifted its holdings in Humacyte by 5,308.2% during the 2nd quarter. Marshall Wace LLP now owns 2,639,194 shares of the company’s stock worth $5,516,000 after buying an additional 2,590,394 shares during the period. 44.71% of the stock is owned by institutional investors.

Key Humacyte News

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $4.00 price target for Humacyte. Its forecast still anticipates a shift to profitability, with projected positive EPS of $0.09 in fiscal 2029 and $0.31 in fiscal 2030, suggesting potential long-term upside if the company successfully commercializes its products.
• Neutral Sentiment: HC Wainwright’s updated estimates project continued losses through fiscal 2028, followed by profitability in 2029 and 2030. The firm now expects fiscal 2026 EPS of ($0.46), fiscal 2027 EPS of ($0.30), and fiscal 2028 EPS of ($0.07).
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across multiple periods, including Q3 2026 to ($0.10) from ($0.09), Q4 2026 to ($0.11) from ($0.09), fiscal 2026 to ($0.46) from ($0.37), and fiscal 2027 to ($0.30) from ($0.26). Longer-term estimates were also cut, with fiscal 2029 EPS lowered to $0.09 from $0.20 and fiscal 2030 EPS to $0.31 from $0.50. These revisions indicate expectations for slower financial improvement.
• Negative Sentiment: Humacyte’s latest quarterly results missed expectations: the company reported a loss of $0.16 per share versus the $0.11 consensus loss, while revenue of $0.41 million was well below the $1.04 million estimate. The substantial operating losses and limited revenue reinforce concerns about cash needs and the timing of commercialization.
• Negative Sentiment: Additional bearish coverage is weighing on investor confidence. Benchmark issued a pessimistic forecast for HUMA. Benchmark Issues Pessimistic Forecast for Humacyte Wall Street Zen also downgraded Humacyte to a Strong Sell rating. Humacyte Lowered to Strong Sell Rating by Wall Street Zen

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.